Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma - Wikidata - wikimedia - TriplyDB

Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma

Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma

http://www.wikidata.org/entity/Q35186682

about

The Traditional Medicine and Modern Medicine from Natural Products Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development Cancer wars: natural products strike back Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention The structural basis of an NADP+-independent dithiol oxidase in FK228 biosynthesis Epigenetic modulators as therapeutic targets in prostate cancer Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Natural products as sources of new drugs over the 30 years from 1981 to 2010 Constraining cyclic peptides to mimic protein structure motifs.Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp Identification and characterization of the spiruchostatin biosynthetic gene cluster enable yield improvement by overexpressing a transcriptional activator.Polycyclic peptide therapeutics.Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia Peptidomimetics via modifications of amino acids and peptide bonds.High throughput screening identifies modulators of histone deacetylase inhibitors Histone deacetylase inhibitors from Burkholderia thailandensis.Gcn5 Modulates the Cellular Response to Oxidative Stress and Histone Deacetylase Inhibition.Violacein induces p44/42 mitogen-activated protein kinase-mediated solid tumor cell death and inhibits tumor cell migration Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.Chromopeptide A, a highly cytotoxic depsipeptide from the marine sediment-derived bacterium Chromobacterium sp. HS-13-94.Bioactivities by a crude extract from the Greenlandic Pseudomonas sp. In5 involves the nonribosomal peptides, nunamycin and nunapeptin.In vitro and in vivo antitumor activity of crude extracts obtained from Brazilian Chromobacterium sp isolates.Epigenetic regulation of peroxiredoxins: Implications in the pathogenesis of cancer.Genome-guided discovery of diverse natural products from Burkholderia sp.Verticillin A Inhibits Leiomyosarcoma and Malignant Peripheral Nerve Sheath Tumor Growth via Induction of Apoptosis.Epigenetics in Stroke Recovery Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration.Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions.Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.Romidepsin for peripheral T-cell lymphoma.Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Natural products as zinc-dependent histone deacetylase inhibitors.Emerging approaches for histone deacetylase inhibitor drug discovery.Nonribosomal peptides and polyketides of Burkholderia: new compounds potentially implicated in biocontrol and pharmaceuticals.Combining Epigenetic and Immunotherapy to Combat Cancer.The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes.

P2860

Q26748266-9A44BB64-E7BE-4208-BB88-C6C909411968 Q26749384-D3BFD402-E774-4C95-B1CC-17512B230849 Q26850074-45E9A5AF-E684-4559-B321-F493E522A210 Q26994739-2F1CBFCF-D93C-4166-9C81-970D4CCEAF5F Q27681843-2F1CC3A2-4893-4383-8DC5-46EDA260695F Q28071912-4A68D3AD-8C3C-42E8-8501-4B19B4DE3B0D Q28075606-9067DD52-34F3-4FCE-B209-1E2D98ED43A7 Q29616640-4BE627F0-97E0-4B70-8F84-00BB719CE7D1 Q30367509-CEE11C21-038E-4C08-ACEA-FB57674815D5 Q30684975-34C9A2FD-8125-40B6-BE64-8381E9E0EDA1 Q34051299-B805487D-AA5E-4C03-A76F-926740E833BA Q34324717-290C6166-AEA4-4686-B7CA-21F630DD3FA4 Q35106637-8B40CC73-37B8-4868-95B3-FA8E3303CE57 Q35120205-9967F1AF-118F-46E8-A61C-B46E2296EB34 Q35195856-B579937F-275A-45A3-89FE-FC6F9E81751E Q35474016-47B10920-8A49-4E55-B582-AC663B7E5BB7 Q35574284-98EEC84B-3E7C-4D24-BC28-CE68B28B9695 Q35628391-A6FD4875-8855-49A1-AE31-B8EA427E382E Q35939690-31E73ECB-4298-4160-A698-6F7FBCF3F8DE Q35998436-4DF573AA-56A0-4FA2-B72E-F00D8357DEA2 Q36224948-3DA31002-C1D9-4DE9-A0C9-00424D5907F2 Q36237655-3D6970F8-DD97-4F6B-B92A-FB16AC56EC66 Q36426194-E5E15643-6051-4607-84E0-5E36E9226DF3 Q37371345-04FAAF0C-F12A-43E8-88F5-BFCE621581E9 Q37514746-DA7E4CF4-8082-4F10-ABE2-E35AF40AB878 Q37625346-BEFEF593-3EF2-4292-A3F1-99480302B130 Q37629512-D2C54456-DFED-40AD-8246-72D1EF27510F Q37724103-CB405474-4598-41D1-A2AD-209DE724035A Q37744742-3A1FC48A-1E95-4557-BC39-4FD19D8EE478 Q38003390-76099CE2-FD30-461B-AA58-14908E3EA13C Q38031633-6B3804E2-E103-4C7A-B84E-5CD25D9CBD0B Q38132813-5ECBC76C-6DB2-4955-88F1-BC0CA093C417 Q38204386-CAFA9F39-F4BA-49E4-B512-2A3EA6802836 Q38240733-7478788B-83DE-4D0D-8121-0CF51FCD5E44 Q38315538-40316930-4344-4AB9-8381-A610FDD8D11D Q38431356-FEDC3AB4-6A4B-4B10-81EA-93C1A901885F Q38762222-2B8FC146-FA5F-4F45-8421-4C5B3B5FB20E Q38779204-A4298298-D884-485B-B695-25040274626E Q38878715-5E71B556-0BA9-4B9B-9BFD-AF28B12BE569 Q38982458-B2A98333-BD85-491B-9972-2145F6F4FD5C

P2860

Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma

http://www.wikidata.org/entity/Q35186682

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Romidepsin (Istodax, NSC 63017 ...... for cutaneous T-cell lymphoma

@ast

Romidepsin (Istodax, NSC 63017 ...... for cutaneous T-cell lymphoma

@en

type

label

Romidepsin (Istodax, NSC 63017 ...... for cutaneous T-cell lymphoma

@ast

Romidepsin (Istodax, NSC 63017 ...... for cutaneous T-cell lymphoma

@en

prefLabel

Romidepsin (Istodax, NSC 63017 ...... for cutaneous T-cell lymphoma

@ast

Romidepsin (Istodax, NSC 63017 ...... for cutaneous T-cell lymphoma

@en

P1433

Q35186682-2AFC50D2-5D67-4F09-B6AF-33017DBB47C3

P1476

Q35186682-21C7BEF1-86C3-4DE5-9872-27BAD8CB14B1

P2093

Q35186682-1C207C79-16B4-4504-8D67-8722F65D24A3

Q35186682-C56C46E6-E1DD-4E41-B9D5-11716CFDF5E5

Q35186682-DF74B778-C417-494D-A477-0891C61F8DC3

Q35186682-E5B43BDF-A0F0-4CC7-B7E3-76F884010616

P2860

Q35186682-0092691F-0168-4D78-9918-210589B43375

Q35186682-00D4323B-06F4-40F8-AF1C-162B0C4BBED5

Q35186682-0462EECA-C6B9-4EEA-892E-83230FA8F03C

Q35186682-0635EE31-9C1B-4577-B6A7-C7271BF12913

Q35186682-0684D5DA-55CD-4D2F-A1E5-D2A8B990F0B1

Q35186682-0AE8DF1B-10E9-4B5B-81DC-9F54EF6632D0

Q35186682-0CE9259D-2925-4F4F-8F1F-E90AEFD252C7

Q35186682-11569599-582E-42E9-B57A-C64C36F211F2

Q35186682-12C6C8C9-CD1A-4DC9-B615-8185499F4BDA

Q35186682-13C63E85-9968-40B2-9205-711BEFFA2B92

P2888

Q35186682-A18C98FC-8326-4FF0-AEF2-86E2833CE513

P304

Q35186682-2A4A55CC-D3CF-4EBA-B908-95074D979EB4

P31

Q35186682-7C823D21-1833-491D-9BFE-94C10D42E205

P356

Q35186682-3DE1FBE5-A143-4FC1-A622-9BB3DE360F1C

P433

Q35186682-30D87886-BE15-4ED8-9E9F-C0E1230F4DF2

P478

Q35186682-3C0A7739-0F2B-4C0A-9400-39CA39B99C7D

P577

Q35186682-8F844000-5328-4CB1-88C8-0D2654107F81

P5875

Q35186682-464F0DCD-59A4-42EF-BA68-24DBE015D254

P6179

Q35186682-4B76CC14-258A-4F88-8441-63DD9793C331

P698

Q35186682-4EE6CB86-4EBF-44D7-AEBA-DD7D72C1D68D

P932

Q35186682-9F45E118-92D1-4AE9-80EC-610338D94D8D

P356

P1433

The Journal of Antibiotics

P1476

Romidepsin (Istodax, NSC 63017 ...... for cutaneous T-cell lymphoma

@en

P2093

Cedric J Pearce

http://www.w3.org/2001/XMLSchema#string

Karen M VanderMolen

http://www.w3.org/2001/XMLSchema#string

Nicholas H Oberlies

http://www.w3.org/2001/XMLSchema#string

William McCulloch

http://www.w3.org/2001/XMLSchema#string

P2860

Improved total synthesis of the potent HDAC inhibitor FK228 (FR-901228)

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor

Roles of histone acetyltransferases and deacetylases in gene regulation

Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia

Clinical and molecular responses in lung cancer patients receiving Romidepsin.

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

P2888

P304

525-531

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/JA.2011.35

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51141462

http://www.w3.org/2001/XMLSchema#string

P6179

1029143550

http://www.w3.org/2001/XMLSchema#string

P698

21587264

http://www.w3.org/2001/XMLSchema#string

P932

3163831

http://www.w3.org/2001/XMLSchema#string